Theralase(R) Extends Warrants
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company, has announced its proposal to extend the expiry date of 10,000,000 share purchase warrants. The warrants, originally issued on September 22, 2022, as part of a private placement, were set to expire on September 22, 2024. The company now proposes to extend this expiry date to September 22, 2027. These warrants are exercisable at $0.35 per share, and all other terms and conditions will remain unchanged. The extension is subject to final acceptance by the TSX Venture Exchange.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), una società farmaceutica in fase clinica, ha annunciato la sua proposta di prorogare la data di scadenza di 10.000.000 di opzioni di acquisto di azioni. Le opzioni, originariamente emesse il 22 settembre 2022, come parte di un collocamento privato, dovevano scadere il 22 settembre 2024. La società propone ora di estendere questa data di scadenza al 22 settembre 2027. Queste opzioni sono esercitabili a $0,35 per azione e tutti gli altri termini e condizioni rimarranno invariati. L'estensione è soggetta all'accettazione finale da parte della TSX Venture Exchange.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), una compañía farmacéutica en etapa clínica, ha anunciado su propuesta de extender la fecha de vencimiento de 10,000,000 de garantías de compra de acciones. Las garantías, emitidas originalmente el 22 de septiembre de 2022, como parte de una colocación privada, estaban programadas para vencer el 22 de septiembre de 2024. La compañía ahora propone ampliar esta fecha de vencimiento hasta el 22 de septiembre de 2027. Estas garantías son ejercitables a $0.35 por acción, y todos los demás términos y condiciones permanecerán sin cambios. La extensión está sujeta a la aceptación final por parte de la TSX Venture Exchange.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF)는 임상 단계의 제약 회사로서 10,000,000개의 주식 매입 보증서의 만료일을 연장하려는 제안을 발표했습니다. 이 보증서는 2022년 9월 22일에 사모 배치의 일환으로 발행되었으며, 원래 만료일은 2024년 9월 22일로 예정되어 있었습니다. 회사는 이제 이 만료일을 2027년 9월 22일로 연장할 것을 제안합니다. 이 보증서는 주당 $0.35로 행사할 수 있으며, 모든 기타 조건은 변함이 없습니다. 연장은 TSX 벤처 거래소의 최종 승인을 조건으로 합니다.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), une société pharmaceutique en phase clinique, a annoncé sa proposition d'étendre la date d'expiration de 10 000 000 de bons de souscription d'actions. Ces bons, initialement émis le 22 septembre 2022 dans le cadre d'un placement privé, devaient expirer le 22 septembre 2024. La société propose désormais d'étendre cette date d'expiration au 22 septembre 2027. Ces bons sont exerçables au prix de 0,35 $ par action et tous les autres termes et conditions resteront inchangés. L'extension est soumise à l'acceptation finale de la TSX Venture Exchange.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seinen Vorschlag bekannt gegeben, das Ablaufdatum von 10.000.000 Aktienoptionsscheinen zu verlängern. Die Optionsscheine, die ursprünglich am 22. September 2022 im Rahmen einer Privatplatzierung ausgegeben wurden, sollten am 22. September 2024 ablaufen. Das Unternehmen schlägt nun vor, dieses Ablaufdatum auf den 22. September 2027 zu verlängern. Diese Optionsscheine können zu einem Preis von 0,35 $ pro Aktie ausgeübt werden, und alle anderen Bedingungen bleiben unverändert. Die Verlängerung steht unter dem Vorbehalt der endgültigen Genehmigung durch die TSX Venture Exchange.
- Extension of warrant expiry date provides additional time for potential exercise
- Maintains potential for future capital inflow at $0.35 per share
- Extension may delay potential capital inflow if warrants were to be exercised sooner
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company proposes to extend the expiry date of 10,000,000 share purchase warrants ("Warrants") from September 22, 2024 to September 22, 2027.
The Warrants were issued on September 22, 2022, pursuant to a private placement involving the issuance of 10,000,000 units of the Company. The Warrants are exercisable at
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's small molecules and their drug formulations, preclinical research, clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all, the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer
X 224
khachey@theralase.com
SOURCE: Theralase Technologies, Inc.
View the original press release on accesswire.com
FAQ
What is Theralase Technologies Inc. (TLTFF) proposing regarding its warrants?
When were the warrants originally issued by Theralase Technologies Inc. (TLTFF)?
What is the exercise price of the warrants for Theralase Technologies Inc. (TLTFF)?
Is the warrant expiry date extension for Theralase Technologies Inc. (TLTFF) finalized?
